Evidence map›Paper›PMID 41744113›Full record

ArticleJournal of the American Heart Association2026

Hypertension in Overweight and Obesity: Sex-Specific Role of 4β-Hydroxycholesterol.

Roosa Rahunen, Heta Merikallio, Valtteri Rinne, Markku J Savolainen, Janne Hukkanen

7 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00985270 phase4completednot on this map

PXR-agonisti Rifampisiinin Vaikutukset Glukoosi-, Lipidi- ja Hormonihomeostaasiin

TypeinterventionalSponsorUniversity of OuluRan2009 to 2010Enrolled12ConditionsGlucose ToleranceArmsRifampicin, Placebo
NCT01293422 phase4completednot on this map

PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon

TypeinterventionalSponsorUniversity of OuluRan2011 to 2011Enrolled12ConditionsGlucose MetabolismArmsRifampicin
NCT01330251 completednot on this map

Laihdutusleikkauksen Vaikutus Diabetekseen

TypeobservationalSponsorUniversity of OuluRan2011 to 2016Enrolled41ConditionsType II Diabetes
NCT01690104 phase4completednot on this map

The Effect of PXR Activation on Blood Pressure Regulation

TypeinterventionalSponsorUniversity of OuluRan2012 to 2013Enrolled22ConditionsBlood Pressure RegulationArmsRifampicin, Placebo
NCT01959763 naactive not recruitingnot on this map

Prevention of the Metabolic Syndrome by a Lifestyle Intervention - an Application of the New Intervention Methods in the Primary Health Care.

TypeinterventionalSponsorUniversity of OuluRan2013 to 2025Enrolled574ConditionsMetabolic Syndrome, Obesity, Overweight, Cardiovascular DiseaseArmsWeight loss counseling program
NCT02329405 phase4completednot on this map

PXR-aktivaation Vaikutus Maksan Rasvoittumiseen

TypeinterventionalSponsorUniversity of OuluRan2014 to 2017Enrolled16ConditionsNon-alcoholic Fatty Liver DiseaseArmsRifampicin, Placebo
NCT04558801 nacompletednot on this map

The Effects of a Mobile Application-based Lifestyle Counselling on Body Weight Loss in Obese Subjects

TypeinterventionalSponsorUniversity of OuluRan2020 to 2022Enrolled200ConditionsObesityArmsMobile application-based lifestyle change program
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal of the American Heart Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Roosa RahunenResearch Unit of Biomedicine and Internal Medicine University of Oulu Finland.ORCID 0009-0009-6640-022X
Heta MerikallioResearch Unit of Biomedicine and Internal Medicine University of Oulu Finland.ORCID 0000-0002-0967-3987
Valtteri RinneAdmescope (Symeres Finland Ltd) Oulu Finland.ORCID 0000-0003-2703-9426
Markku J SavolainenResearch Unit of Biomedicine and Internal Medicine University of Oulu Finland.ORCID 0000-0002-2557-6423
Janne HukkanenResearch Unit of Biomedicine and Internal Medicine University of Oulu Finland.ORCID 0000-0003-4981-0525

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have previously proposed novel pathway in overweight/obesity-induced hypertension involving plasma 4β-hydroxycholesterol (4βHC), an agonist for LXR (liver X receptor), as a hypotensive factor. The aim was to determine sex-specific roles of 4βHC in obesity-induced hypertension in a cohort without blood pressure (BP) medications.

methodsA study population (n=645) with wide body mass index range (19-47 kg/m

resultsPlasma 4βHC correlated negatively with systolic BP and body mass index in both sexes. In men (n=282), the correlation between 4βHC and systolic BP was

conclusionsPlasma 4βHC was associated inversely with BP, especially in women, whereas pharmacologically elevated 4βHC seemed to affect men more pronouncedly. Plasma 4βHC may have a sex-specific role in overweight- and obesity-induced hypertension. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifiers: NCT00985270, NCT01293422, NCT01690104, NCT02329405, NCT01330251, NCT01959763, and NCT04558801.

Indexed as

Blood PressureHydroxycholesterolsHypertensionObesityOverweightAdultAgedBiomarkersBody Mass IndexClinical Trials as TopicFemaleHumansMaleMiddle AgedSex FactorsBiomarkerscholest-5-ene-3,4-diolHydroxycholesterols4β‐hydroxycholesterolblood pressurehypertensionobesitysex differences

Identifiers

PMID41744113
PMCPMC13055684

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.